Health diplomacy in action: The cancer legacy of the Good Friday Agreement.

2023 marks the 25th anniversary of the Good Friday Agreement, which led peace in Northern Ireland. As well as its impact on peace and reconciliation, the Good Friday Agreement has also had a lasting positive impact on cancer research and cancer care across the island of Ireland. Pursuant to the Good Friday Agreement, a Memorandum of Understanding (MOU) was signed between the respective Departments of Health in Ireland, Northern Ireland and the US National Cancer Institute (NCI), giving rise to the Ireland - Northern Ireland - National Cancer Institute Cancer Consortium, an unparalleled tripartite agreement designed to nurture and develop linkages between cancer researchers, physicians and allied healthcare professionals across Ireland, Northern Ireland and the US, delivering world class research and better care for cancer patients on the island of Ireland and driving research and innovation in the US.
Competing Interests: Declaration of Competing Interest ML declares honoraria from Bayer, Carnall Farrar, Novartis, Pfizer and Roche unrelated to this work, GKA declares research support from Agenus, Arcus, Astra Zeneca, BioNtech, BMS, Elicio, Genentech/Roche, Helsinn, Parker Institute, Pertzye, Puma, QED, Yiviva, and consulting support from Astellas, Astra Zeneca, Autem, Berry Genomics, BioNtech, Boehringer Ingelheim, BMS, Eisai, Exelixis, Fibriogen, Genentech/Roche, Incyte, Ipsen, Merck, Merus, Neogene, Novartis, Servier, Tempus, Thetis, Vector, Yiviva unrelated to this work RDL declares interests as Founder of CV6 Therapeutics (NI) Ltd, Belfast, UK unrelated to this work MAG declares interests as Founder of Aviceda Therapeutics and Aviceda Glycotech and as an equity shareholder of Aviceda Glycotech Ltd and Aviceda Therapeutics Inc unrelated to this work MLo declares advisory roles with AstraZeneca, Roche/Genentech, Servier and research funding from Astellas Pharma, Basilea, Exelixis and MSD unrelated to this work WMG declares interests as Co-Founder and Chief Scientific Officer, OncoAssure and Scientific Advisory Board member, Carrick Therapeutics unrelated to this work RS, KDMcC, DK, JF, WD, EM, JLG, CJS, DBL, ACC, NO, SJC, SG declare no competing interests, The opinions expressed in this article are the authors own and do not reflect the view of the National Institutes of Health, the Department of Health and Human Services, or the United States Government.
(Copyright © 2023. Published by Elsevier Ltd.)